Cargando…

Construction of PR39 recombinant AAV under control of the HRE promoter and the effect of recombinant AAV on gene therapy of ischemic heart disease

The objective of this study was to investigate the effect of the PR39 recombinant adeno-associated virus (AAV) controlled by the hypoxia-responsive element (HRE) on gene therapy of ischemic heart disease. The minimal HRE was artificially synthesized and the AAV vector controlled by HRE was introduce...

Descripción completa

Detalles Bibliográficos
Autores principales: SUN, LIJUN, HAO, YUEWEN, NIE, XIAOWEI, ZHANG, XUEXIN, YANG, GUANGXIAO, WANG, QUANYING
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493712/
https://www.ncbi.nlm.nih.gov/pubmed/23226731
http://dx.doi.org/10.3892/etm.2012.674
_version_ 1782249311281610752
author SUN, LIJUN
HAO, YUEWEN
NIE, XIAOWEI
ZHANG, XUEXIN
YANG, GUANGXIAO
WANG, QUANYING
author_facet SUN, LIJUN
HAO, YUEWEN
NIE, XIAOWEI
ZHANG, XUEXIN
YANG, GUANGXIAO
WANG, QUANYING
author_sort SUN, LIJUN
collection PubMed
description The objective of this study was to investigate the effect of the PR39 recombinant adeno-associated virus (AAV) controlled by the hypoxia-responsive element (HRE) on gene therapy of ischemic heart disease. The minimal HRE was artificially synthesized and the AAV vector controlled by HRE was introduced with NT4-TAT-His-PR39 to investigate the expression of AAV-PR39 in hypoxic vascular endothelial cells (VEC) of human umbilical vein (CRL-1730 cell line) and the angiogenesis-promoting effect in pigs with acute myocardial infraction (AMI). The minimal HRE/CMV was designed and artificially synthesized using the PCR method and cloned with the T vector cloning method. The pSS-HRE-CMV-NT4-6His-PR39-PolyA-AAV plasmid was constructed. Using the calcium phosphate precipitation method, HEK-293 cells were co-transfected with three plasmids to produce the recombinant virus. An equal volume of pSS-HRE-CMV-NT4-6His-PR39-PolyAAAV and enterovirus (EV, blank virus) was transfected into CRL-1730 cell lines, respectively. The immunohistochemical method was used to assay the expression of 6xHis in CRL-1730 cell lines and the expression of PR39 under hypoxia. Eighteen AMI miniature pigs were randomized into the experimental group (HRE-AAV-PR39 group), control group 1 (physical saline group) and control group 2 (EV group). The area of ischemia was assessed with conventional MRI and myocardium perfusion MRI. Pigs were sacrificed at preset time-points to obtain samples of ischemic myocardium. Morphological and pathological data were collected. According to data in the literature and databases, the minimal HRE was designed and synthesized with the PCR method. A large number of HREs were connected to modified pSSHGAAV (pSSV9int-/XbaI) vector followed by insertion of the NT4-6His-PR39 gene segment and, thus, the recombinant plasmid pSS-HRE-CMV-NT4-6His-PR39-PolyA-AAV was successfully constructed. The expression of 6xHis in CRL-1730 cells under the regulation of HRE was assayed using the immunohistochemical method and results showed that the expression was positive in the experimental group. Myocardium perfusion MRI displayed that the infracted area significantly decreased under the action of pSS-HRE-CMV-NT4-PR39-PolyA-AAV. The artificial minimal HRE in CRL-1730 cells effectively and rapidly regulates the expression of the downstream gene NT4-TAT-His-PR39 of the CMV promoter. Recombinant pSS-HRE-CMV-NT4-PR39-Poly-AAAV promotes neoangiogenesis in the ischemic area, reduces the area of infarction and improves heart function.
format Online
Article
Text
id pubmed-3493712
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-34937122012-12-06 Construction of PR39 recombinant AAV under control of the HRE promoter and the effect of recombinant AAV on gene therapy of ischemic heart disease SUN, LIJUN HAO, YUEWEN NIE, XIAOWEI ZHANG, XUEXIN YANG, GUANGXIAO WANG, QUANYING Exp Ther Med Articles The objective of this study was to investigate the effect of the PR39 recombinant adeno-associated virus (AAV) controlled by the hypoxia-responsive element (HRE) on gene therapy of ischemic heart disease. The minimal HRE was artificially synthesized and the AAV vector controlled by HRE was introduced with NT4-TAT-His-PR39 to investigate the expression of AAV-PR39 in hypoxic vascular endothelial cells (VEC) of human umbilical vein (CRL-1730 cell line) and the angiogenesis-promoting effect in pigs with acute myocardial infraction (AMI). The minimal HRE/CMV was designed and artificially synthesized using the PCR method and cloned with the T vector cloning method. The pSS-HRE-CMV-NT4-6His-PR39-PolyA-AAV plasmid was constructed. Using the calcium phosphate precipitation method, HEK-293 cells were co-transfected with three plasmids to produce the recombinant virus. An equal volume of pSS-HRE-CMV-NT4-6His-PR39-PolyAAAV and enterovirus (EV, blank virus) was transfected into CRL-1730 cell lines, respectively. The immunohistochemical method was used to assay the expression of 6xHis in CRL-1730 cell lines and the expression of PR39 under hypoxia. Eighteen AMI miniature pigs were randomized into the experimental group (HRE-AAV-PR39 group), control group 1 (physical saline group) and control group 2 (EV group). The area of ischemia was assessed with conventional MRI and myocardium perfusion MRI. Pigs were sacrificed at preset time-points to obtain samples of ischemic myocardium. Morphological and pathological data were collected. According to data in the literature and databases, the minimal HRE was designed and synthesized with the PCR method. A large number of HREs were connected to modified pSSHGAAV (pSSV9int-/XbaI) vector followed by insertion of the NT4-6His-PR39 gene segment and, thus, the recombinant plasmid pSS-HRE-CMV-NT4-6His-PR39-PolyA-AAV was successfully constructed. The expression of 6xHis in CRL-1730 cells under the regulation of HRE was assayed using the immunohistochemical method and results showed that the expression was positive in the experimental group. Myocardium perfusion MRI displayed that the infracted area significantly decreased under the action of pSS-HRE-CMV-NT4-PR39-PolyA-AAV. The artificial minimal HRE in CRL-1730 cells effectively and rapidly regulates the expression of the downstream gene NT4-TAT-His-PR39 of the CMV promoter. Recombinant pSS-HRE-CMV-NT4-PR39-Poly-AAAV promotes neoangiogenesis in the ischemic area, reduces the area of infarction and improves heart function. D.A. Spandidos 2012-11 2012-08-20 /pmc/articles/PMC3493712/ /pubmed/23226731 http://dx.doi.org/10.3892/etm.2012.674 Text en Copyright © 2012, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
SUN, LIJUN
HAO, YUEWEN
NIE, XIAOWEI
ZHANG, XUEXIN
YANG, GUANGXIAO
WANG, QUANYING
Construction of PR39 recombinant AAV under control of the HRE promoter and the effect of recombinant AAV on gene therapy of ischemic heart disease
title Construction of PR39 recombinant AAV under control of the HRE promoter and the effect of recombinant AAV on gene therapy of ischemic heart disease
title_full Construction of PR39 recombinant AAV under control of the HRE promoter and the effect of recombinant AAV on gene therapy of ischemic heart disease
title_fullStr Construction of PR39 recombinant AAV under control of the HRE promoter and the effect of recombinant AAV on gene therapy of ischemic heart disease
title_full_unstemmed Construction of PR39 recombinant AAV under control of the HRE promoter and the effect of recombinant AAV on gene therapy of ischemic heart disease
title_short Construction of PR39 recombinant AAV under control of the HRE promoter and the effect of recombinant AAV on gene therapy of ischemic heart disease
title_sort construction of pr39 recombinant aav under control of the hre promoter and the effect of recombinant aav on gene therapy of ischemic heart disease
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493712/
https://www.ncbi.nlm.nih.gov/pubmed/23226731
http://dx.doi.org/10.3892/etm.2012.674
work_keys_str_mv AT sunlijun constructionofpr39recombinantaavundercontrolofthehrepromoterandtheeffectofrecombinantaavongenetherapyofischemicheartdisease
AT haoyuewen constructionofpr39recombinantaavundercontrolofthehrepromoterandtheeffectofrecombinantaavongenetherapyofischemicheartdisease
AT niexiaowei constructionofpr39recombinantaavundercontrolofthehrepromoterandtheeffectofrecombinantaavongenetherapyofischemicheartdisease
AT zhangxuexin constructionofpr39recombinantaavundercontrolofthehrepromoterandtheeffectofrecombinantaavongenetherapyofischemicheartdisease
AT yangguangxiao constructionofpr39recombinantaavundercontrolofthehrepromoterandtheeffectofrecombinantaavongenetherapyofischemicheartdisease
AT wangquanying constructionofpr39recombinantaavundercontrolofthehrepromoterandtheeffectofrecombinantaavongenetherapyofischemicheartdisease